Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer

CONCLUSION: Tisotumab vedotin was unlikely cost-effective compared to chemotherapy for recurrent or metastatic cervical cancer patients at a willingness-to-pay threshold of $150,000/QALY from the perspective of a U.S. payer. Lowering the prices of tisotumab vedotin could potentially enhance its cost-effectiveness.PMID:38330381 | DOI:10.3802/jgo.2024.35.e58
Source: Journal of Gynecologic Oncology - Category: OBGYN Authors: Source Type: research